{"uri":"supernatant-transfer-assay-and-transwell-assay-h3vb8n6","version_id":"0","protocol_name":"Supernatant Transfer Assay  and Transwell\u00ae Assay","protocol_name_html":"Supernatant Transfer Assay  and Transwell\u00ae Assay","is_prepublished":"0","can_edit":"0","parent_id":null,"api_version":"1","is_new_mode":"1","last_modified":"1522216802","type_id":"1","link":"https:\/\/doi.org\/10.1371\/journal.pone.0183390","fork_id":"","public_fork_note":"","number_of_steps":"4","has_versions":"0","first_published_date":"1495050170","publish_date":"2017-05-17 19:42:50","documents":null,"have_protocol_in_step":"0","is_protocol_in_step":"0","vendor_name":"Contributed by users","vendor_link":"https:\/\/www.protocols.io","vendor_logo":"\/img\/vendors\/1.png","mod_mins":"-45","mod_secs":"1","description":"<p>This protocol describes two methods for assessing whether soluble factors alone or a combination of soluble factors and T cells are responsible for bystander killing: (1) Supernatant transfer assays and (2)\u00a0Transwell\u00ae assays.<\/p>","is_bookmarked":"0","can_reassign":"1","before_start":"","has_guidelines":"0","materials":[],"warning":"","version_class":"5973","public":"1","is_owner":"1","is_original_owner":"1","created_on":"1494981407","protocol_affiliation":"Amgen Inc.","affiliation":null,"doi":"dx.doi.org\/10.17504\/protocols.io.h3vb8n6","doi_status":"2","changed_fork_steps":null,"profile_url":"x2y284w2t2","protocol_img":"https:\/\/www.protocols.io\/img\/default_protocol.png","profile_image":"\/img\/avatars\/006.png","full_name":"Sandra Ross","created_by":"Sandra Ross","private_link":"583E0A1CAE172670E8F8A4CB065AE749","original_img":"1","username":"sandra-ross","is_retracted":"0","retraction_reason":null,"plos_id":"10.1371\/journal.pone.0183390","manuscript_citation":"Ross SL,  Sherman M,  McElroy PL,  Lofgren JA,  Moody G,  Baeuerle PA,  Coxon A,  Arvedson T, Bispecific T cell engager (BiTE) antibody constructs can mediate bystander tumor cell killing. PLoS ONE  12(8). doi: <a target=\"_blank\" href=\"https:\/\/dx.doi.org\/10.1371\/journal.pone.0183390\">10.1371\/journal.pone.0183390<\/a> ","journal_name":"PLOS One","is_donations_disabled":"0","is_donations_disabled_by_user":"9","item_record_id":243362,"fork_info":[],"compare_forks":[],"protocols":[],"groups":[],"number_of_shared_runs":[],"ownership_history":[],"keywords":"","transfer_to_user":[],"sub_transfer":false,"is_transfer_pending":false,"number_of_bookmarks":"0","collections":[{"protocol_name":"Collection of protocols accompanying \"Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing\"","protocol_name_html":"Collection of protocols accompanying \"Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing\"","uri":"collection-of-protocols-accompanying-bispecific-t-ib8carw","username":"sandra-ross","profile_image":"\/img\/avatars\/006.png","protocol_img":"https:\/\/www.protocols.io\/img\/default_protocol.png","full_name":"Sandra Ross"}],"tags":[],"archived":0,"sub_authors":[],"sub_protocols_number":0,"can_edit_shared":0,"shared_runs":[],"is_shared_run":0,"is_shared":1,"banner":null,"contact_badges":[{"badge_id":"4","badge_image":"\/img\/badges\/gold.svg","badge_description":"Gold power author!"},{"badge_id":"5","badge_image":"\/img\/badges\/earlyadopter.svg","badge_description":"Early adopter"}],"number_of_comments":0,"is_locked":0,"is_locked_by":false,"authors":"Sandra L. Ross, Marika Sherman, Patricia L. McElroy, Julie A. Lofgren, Gordon Moody, Patrick A. Baeuerle, Angela Coxon, Tara Arvedson","authors_list":[{"name":"Sandra L. Ross","affiliation":"Amgen Inc.","username":null,"profile_image":null},{"name":" Marika Sherman","affiliation":"Amgen Inc.","username":null,"profile_image":null},{"name":" Patricia L. McElroy","affiliation":"Amgen Inc.","username":null,"profile_image":null},{"name":" Julie A. Lofgren","affiliation":"Amgen Inc.","username":null,"profile_image":null},{"name":" Gordon Moody","affiliation":"Amgen Inc.","username":null,"profile_image":null},{"name":" Patrick A. Baeuerle","affiliation":"Amgen Inc.","username":null,"profile_image":null},{"name":" Angela Coxon","affiliation":"Amgen Inc.","username":null,"profile_image":null},{"name":" Tara Arvedson","affiliation":"Amgen Inc.","username":null,"profile_image":null}],"user":{"profile_image":"\/img\/avatars\/006.png","username":"sandra-ross","full_name":"Sandra Ross","created_by":"Sandra Ross"},"access":{"can_view":"1","can_remove":"0","can_add":"0","can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":"0","can_move":"1","can_transfer":"1","can_download":"1","is_locked":"0"},"is_contact_suspended":0,"guidelines":"","status_id":"1","is_research":"1","status_info":null,"steps":[{"id":"505603","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"B1B9C9AFCA0D4B448AB421DAC466B56D","previous_guid":"DBEA033F883D4516ACBF1A7820BBA3BC","previous_id":"505608","last_modified":"1495044934","components":[{"component_id":"820472","previous_id":0,"original_id":"0","guid":"6BA11E8C601A43A3B32DB05BD5C9A02A","previous_guid":null,"component_type_id":"1","data_id":"0","data":"<p>See also Materials list in\u00a0TDCC protocol.<\/p>\n<p>\u00a0<\/p>\n<p>HTS Transwell-96 System, PET membrane Corning #3392 or #3380 1 \u03bcm<\/p>\n<p>HTS Transwell-96 Well Plate, PC membrane Corning #3387 or #3388 5 \u03bcm<\/p>\n<p>HTS Transwell-96 receiver plate, tissue culture treated Corning #3382 clear plate<\/p>\n<p>HTS Transwell-96 receiver plate, tissue culture treated Corning #3583 black plate, including bottom<\/p>\n<p>\u00a0<\/p>","order_id":"0","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>See also Materials list in\u00a0TDCC protocol.<\/p>\n<p>\u00a0<\/p>\n<p>HTS Transwell-96 System, PET membrane Corning #3392 or #3380 1 \u03bcm<\/p>\n<p>HTS Transwell-96 Well Plate, PC membrane Corning #3387 or #3388 5 \u03bcm<\/p>\n<p>HTS Transwell-96 receiver plate, tissue culture treated Corning #3382 clear plate<\/p>\n<p>HTS Transwell-96 receiver plate, tissue culture treated Corning #3583 black plate, including bottom<\/p>\n<p>\u00a0<\/p>"},"is_project":0},{"component_id":"820473","previous_id":"820472","original_id":"0","guid":"3394675AB83F420D81579AD83BDBB3B3","previous_guid":"6BA11E8C601A43A3B32DB05BD5C9A02A","component_type_id":"6","data_id":"0","data":"Materials","order_id":"1","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Materials"},"is_project":0}]},{"id":"505608","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"DBEA033F883D4516ACBF1A7820BBA3BC","previous_guid":null,"previous_id":"0","last_modified":"1495041650","components":[{"component_id":"820502","previous_id":0,"original_id":"0","guid":"BAF162D816E243BA9E11722B35D9C946","previous_guid":null,"component_type_id":"1","data_id":"0","data":"<p>This protocol describes methods to assess the contribution of soluble factors and BiTE\u00ae<strong>-<\/strong>activated T cells in bystander killing. Two methods are used:<\/p>\n<p>\u00a0(1) Supernatant transfer assays from BiTE\u00ae- + T cell-treated target positive cells to target-negative cells and (2)\u00a0Transwell\u00ae assays in which a membrane separates BiTE\u00ae- + T cell-treated target-positive cultures from target-negative cultures, restricting movement of T cells but not soluble factors.<\/p>\n<p>\u00a0<\/p>\n<p>These assays are modifications of the standard TDCC protocol. Please refer to TDCC protocol for cell treatments and assay set-up.<\/p>","order_id":"0","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>This protocol describes methods to assess the contribution of soluble factors and BiTE\u00ae<strong>-<\/strong>activated T cells in bystander killing. Two methods are used:<\/p>\n<p>\u00a0(1) Supernatant transfer assays from BiTE\u00ae- + T cell-treated target positive cells to target-negative cells and (2)\u00a0Transwell\u00ae assays in which a membrane separates BiTE\u00ae- + T cell-treated target-positive cultures from target-negative cultures, restricting movement of T cells but not soluble factors.<\/p>\n<p>\u00a0<\/p>\n<p>These assays are modifications of the standard TDCC protocol. Please refer to TDCC protocol for cell treatments and assay set-up.<\/p>"},"is_project":0},{"component_id":"820479","previous_id":"820502","original_id":"0","guid":"4FDF2A64344547FE955D94456B019B62","previous_guid":"BAF162D816E243BA9E11722B35D9C946","component_type_id":"6","data_id":"0","data":"Overview","order_id":"1","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Overview"},"is_project":0}]},{"id":"505841","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"6D2D40D024C94E9CA82A287E45BE247A","previous_guid":"B1B9C9AFCA0D4B448AB421DAC466B56D","previous_id":"505603","last_modified":"1495042134","components":[{"component_id":"820956","previous_id":0,"original_id":"0","guid":"1899E0DAF4F14360BAE7B877FE47A3A4","previous_guid":null,"component_type_id":"1","data_id":"0","data":"<p>For 96-well assays, each well contains a final volume of 200 \u00b5l. Plan for setting up cells in separate ViewPlates to allow for:<\/p>\n<ul>\n<li>Supernatant transferred directly (medium + cells)<\/li>\n<li>Supernatant clarified by centrifugation (medium only)<\/li>\n<li>No transfer control<\/li>\n<\/ul>\n<p>1. Prepare target-positive cells cells:<\/p>\n<ul>\n<li>Detach adherent target cells, count and dilute cells (e.g. NUGC-4) in a mixture with T cells at desired E:T ratio (10:1 typically used) in 160 \u00b5l, e.g. 10:1 = 10,000 target cells and 100,000 T cells per well<\/li>\n<li>Add 40 \u00b5l per well of BiTE\u00ae dilution or assay medium to plates<\/li>\n<li>Add 160 \u00b5l per well target cells plus T cell mixture to plates<\/li>\n<li>Allow plates to equilibrate for 30 min. at room temperature<\/li>\n<li>Incubate at 37\u00b0C, 5% CO2 for 48 hours<\/li>\n<\/ul>\n<p>3. Prepare target-negative cell plates (e.g. SW620) on day of supernatant transfer:<\/p>\n<ul>\n<li>Detach adherent target-negative cells, count and dilute cells in a mixture with T cells at desired E:T ratio in 160 \u00b5l, e.g. 10:1 = 10,000 target cells and 100,000 T cells per well<\/li>\n<li>Add 160 \u00b5l target-negative cells plus T cell mixture to a fresh 96-well ViewPlate<\/li>\n<li>Allow plates to equilibrate for 30 min. at room temperature<\/li>\n<li>Incubate at 37\u00b0C, 5% CO2 for 5 hours to allow cells to adhere.<\/li>\n<\/ul>\n<p>4. Set up supernatant transfer assay:<\/p>\n<ul>\n<li>Remove media from target-negative cells by inverting plate and blot edges on paper towel<\/li>\n<li>Plate 1: Transfer directly 0.160 ml crude supernatant from target-positive NUGC-4 plate to plate containing target-negative SW620 cells<\/li>\n<li>Plate 2: Transfer carefully 0.160 ml clarified supernatant from target-positive NUGC-4 plate to plate containing target-negative SW620 cells. (NUGC-4 plate first centrifuged at 400 x g for 5 min.)<\/li>\n<li>Plate 3: No transfer control-add fresh BiTE\u00ae dilutions and T cells<\/li>\n<li>Incubate at 37\u00b0C, 5% CO2 for 48 hours<\/li>\n<\/ul>\n<p>5.\u00a0Perform cytotoxicity assay (imaging or CellTiter-Glo\u00ae - see TDCC protocol).<\/p>","order_id":"0","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>For 96-well assays, each well contains a final volume of 200 \u00b5l. Plan for setting up cells in separate ViewPlates to allow for:<\/p>\n<ul>\n<li>Supernatant transferred directly (medium + cells)<\/li>\n<li>Supernatant clarified by centrifugation (medium only)<\/li>\n<li>No transfer control<\/li>\n<\/ul>\n<p>1. Prepare target-positive cells cells:<\/p>\n<ul>\n<li>Detach adherent target cells, count and dilute cells (e.g. NUGC-4) in a mixture with T cells at desired E:T ratio (10:1 typically used) in 160 \u00b5l, e.g. 10:1 = 10,000 target cells and 100,000 T cells per well<\/li>\n<li>Add 40 \u00b5l per well of BiTE\u00ae dilution or assay medium to plates<\/li>\n<li>Add 160 \u00b5l per well target cells plus T cell mixture to plates<\/li>\n<li>Allow plates to equilibrate for 30 min. at room temperature<\/li>\n<li>Incubate at 37\u00b0C, 5% CO2 for 48 hours<\/li>\n<\/ul>\n<p>3. Prepare target-negative cell plates (e.g. SW620) on day of supernatant transfer:<\/p>\n<ul>\n<li>Detach adherent target-negative cells, count and dilute cells in a mixture with T cells at desired E:T ratio in 160 \u00b5l, e.g. 10:1 = 10,000 target cells and 100,000 T cells per well<\/li>\n<li>Add 160 \u00b5l target-negative cells plus T cell mixture to a fresh 96-well ViewPlate<\/li>\n<li>Allow plates to equilibrate for 30 min. at room temperature<\/li>\n<li>Incubate at 37\u00b0C, 5% CO2 for 5 hours to allow cells to adhere.<\/li>\n<\/ul>\n<p>4. Set up supernatant transfer assay:<\/p>\n<ul>\n<li>Remove media from target-negative cells by inverting plate and blot edges on paper towel<\/li>\n<li>Plate 1: Transfer directly 0.160 ml crude supernatant from target-positive NUGC-4 plate to plate containing target-negative SW620 cells<\/li>\n<li>Plate 2: Transfer carefully 0.160 ml clarified supernatant from target-positive NUGC-4 plate to plate containing target-negative SW620 cells. (NUGC-4 plate first centrifuged at 400 x g for 5 min.)<\/li>\n<li>Plate 3: No transfer control-add fresh BiTE\u00ae dilutions and T cells<\/li>\n<li>Incubate at 37\u00b0C, 5% CO2 for 48 hours<\/li>\n<\/ul>\n<p>5.\u00a0Perform cytotoxicity assay (imaging or CellTiter-Glo\u00ae - see TDCC protocol).<\/p>"},"is_project":0},{"component_id":"820940","previous_id":"820956","original_id":"0","guid":"B2DEE63B685E41B2AEE30245C7AA78D1","previous_guid":"1899E0DAF4F14360BAE7B877FE47A3A4","component_type_id":"6","data_id":"0","data":"Supernatant transfer assay","order_id":"1","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Supernatant transfer assay"},"is_project":0}]},{"id":"506281","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"F00DFC3941224088BADD732040295A2F","previous_guid":"6D2D40D024C94E9CA82A287E45BE247A","previous_id":"505841","last_modified":"1495042385","components":[{"component_id":"821869","previous_id":0,"original_id":"0","guid":"DB061BB5FEFA4E8292D3193D75DFB759","previous_guid":null,"component_type_id":"1","data_id":"0","data":"<p>For 96-well transwell assays, each well contains a final volume of 310 \u00b5l<\/p>\n<ul>\n<li>Bottom receiver plate: 200 \u00b5l target-negative (or target-positive for positive control) cells + 35 \u00b5l assay medium<\/li>\n<li>Top chamber insert:\u00a0 35 \u00b5l 10X BiTE\u00ae dilutions + 40 \u00b5l target-positive cells\/T cell mixture (typically 10:1 E:T ratio)<\/li>\n<\/ul>\n<p>1. Prepare target cells:<\/p>\n<ul>\n<li>Detach adherent target-positive cells, count and dilute to 10,000 cells\/well, 200 \u00b5l\/well. Also, dilute target cells in a mixture with T cells at desired E:T ratio in 40 \u00b5l, \u00a0e.g. 10:1 = 10,000 target cells and 100,000 T cells per well<\/li>\n<\/ul>\n<p>2. Set up assay:<\/p>\n<ul>\n<li>Add 35 \u00b5l assay medium to wells in bottom of receiver plate<\/li>\n<li>Add 200 \u00b5l target-negative (or target-positive for positive control) cells to wells in bottom of receiver plate (10,000 cells\/well)<\/li>\n<li>Carefully place insert on top of the receiver plate<\/li>\n<li>Add 35 \u00b5l of BiTE\u00ae dilution to top chamber of insert<\/li>\n<li>Add 40 \u00b5l target-positive cells\/T cell mixture to top chamber of insert<\/li>\n<li>Allow plates to equilibrate for 30 min. at room temperature<\/li>\n<li>Incubate at 37\u00b0C, 5% CO2 for 72 hours<\/li>\n<\/ul>\n<p>3. Perform cytotoxicity assay on the cells in the bottom chambers\/receiver plates (imaging or CellTiter-Glo\u00ae - see TDCC protocol).<\/p>","order_id":"0","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>For 96-well transwell assays, each well contains a final volume of 310 \u00b5l<\/p>\n<ul>\n<li>Bottom receiver plate: 200 \u00b5l target-negative (or target-positive for positive control) cells + 35 \u00b5l assay medium<\/li>\n<li>Top chamber insert:\u00a0 35 \u00b5l 10X BiTE\u00ae dilutions + 40 \u00b5l target-positive cells\/T cell mixture (typically 10:1 E:T ratio)<\/li>\n<\/ul>\n<p>1. Prepare target cells:<\/p>\n<ul>\n<li>Detach adherent target-positive cells, count and dilute to 10,000 cells\/well, 200 \u00b5l\/well. Also, dilute target cells in a mixture with T cells at desired E:T ratio in 40 \u00b5l, \u00a0e.g. 10:1 = 10,000 target cells and 100,000 T cells per well<\/li>\n<\/ul>\n<p>2. Set up assay:<\/p>\n<ul>\n<li>Add 35 \u00b5l assay medium to wells in bottom of receiver plate<\/li>\n<li>Add 200 \u00b5l target-negative (or target-positive for positive control) cells to wells in bottom of receiver plate (10,000 cells\/well)<\/li>\n<li>Carefully place insert on top of the receiver plate<\/li>\n<li>Add 35 \u00b5l of BiTE\u00ae dilution to top chamber of insert<\/li>\n<li>Add 40 \u00b5l target-positive cells\/T cell mixture to top chamber of insert<\/li>\n<li>Allow plates to equilibrate for 30 min. at room temperature<\/li>\n<li>Incubate at 37\u00b0C, 5% CO2 for 72 hours<\/li>\n<\/ul>\n<p>3. Perform cytotoxicity assay on the cells in the bottom chambers\/receiver plates (imaging or CellTiter-Glo\u00ae - see TDCC protocol).<\/p>"},"is_project":0},{"component_id":"821858","previous_id":"821869","original_id":"0","guid":"0FD5398C103048849F2DD1946AAE09D5","previous_guid":"DB061BB5FEFA4E8292D3193D75DFB759","component_type_id":"6","data_id":"0","data":"Transwell\u00ae assay","order_id":"1","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Transwell\u00ae assay"},"is_project":0}]}]}